Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

Publication | Closed Access

DOI

482

Citations

References

2008

Year

Jean‐Michel Molina, Jaime Andrade‐Villanueva, Juan Echevarría, Ploenchan Chetchotisakd, Jorge Alberto Corral, Neal David, Graeme Moyle, Marco Mancini, Lisa Percival, Rong Yang,

The Lancet

Treatment And PreventionAntiviral Drug DevelopmentClinical TrialsAntiviral TherapyVirologyCastle StudyWeek EfficacyPharmacotherapySafety ResultsAntiviral DrugHivMedicine